Skip to main content
峆一药业 logo

峆一药业 — Investor Relations & Filings

Ticker · 920478 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2026-04-15 AGM Information
Country CN China
Listing Beijing Stock Exchange 920478

About 峆一药业

http://www.heryipharma.com/

Anhui Heyi Pharmaceutical Co., Ltd. specializes in the research, development, production, and sales of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company focuses on providing high-quality chemical products for various therapeutic areas, including cardiovascular, central nervous system, and anti-infective treatments. With a strong emphasis on technological innovation and quality control, it operates advanced manufacturing facilities that adhere to international standards. Its product portfolio includes key intermediates for widely used medications, supporting both domestic and global pharmaceutical supply chains. The company leverages its expertise in complex chemical synthesis to offer customized solutions and reliable supply to its partners in the life sciences sector.

Recent filings

Filing Released Lang Actions
关于召开2025年年度股东会通知公告（提供网络投票）
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2025 Annual General Meeting (AGM) of 安徽峆一药业股份有限公司. It details the meeting date, voting methods (including online voting), agenda items to be discussed and voted on, registration procedures, and other logistical information. The document does not contain the actual annual report, financial statements, or detailed financial data but rather serves as an announcement to shareholders about the upcoming AGM and the related voting process. The document length is 3334 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2026-04-15 Chinese
2025年度独立董事述职报告（潘平）
Board/Management Information Classification · 95% confidence The document is a detailed report by an independent director of Anhui Xuyi Pharmaceutical Co., Ltd. for the year 2025. It includes the director's duties, attendance at board and committee meetings, communication with auditors, oversight of financial reports, and evaluation of governance and compliance matters. The content focuses on the independent director's annual performance and oversight activities rather than presenting financial statements or audit results. It is not an annual report, audit report, or earnings release. It is also not a simple announcement or certification but a substantive report on board/management oversight and governance activities. Therefore, the document fits best under Board/Management Information (MANG), which covers announcements of changes or reports related to the company's board or senior management activities.
2026-04-15 Chinese
国元证券股份有限公司关于安徽峆一药业股份有限公司2025年度募集资金存放、管理与实际使用情况的专项核查意见
Audit Report / Information Classification · 80% confidence The document is a special verification opinion (专项核查意见) issued by the sponsor and independent accounting firm on the deposit, management, and actual use of funds raised in the public offering. It contains detailed audit findings, account balances, and certification of compliance with listing regulations. It is not an Annual Report (10-K), interim/quarterly report, earnings release, or investor presentation, but rather a standalone audit/verification report. Therefore, it falls under Audit Report / Information (AR). FY 2025
2026-04-15 Chinese
内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It is issued by a certified public accounting firm and addresses the effectiveness of internal control over financial reporting as of December 31, 2025. The document includes an audit opinion on internal control effectiveness, references relevant auditing standards, and is signed and dated April 14, 2026. The content is focused on the audit of internal controls rather than a full annual report or financial statements. The document length is 1679 characters, which is relatively short but contains substantive audit content, not just an announcement. Therefore, it fits the category of an Audit Report / Information (AR) rather than an Annual Report (10-K) or Regulatory Filing (RNS). FY 2025
2026-04-15 Chinese
关于拟修订《公司章程》公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the proposed amendment to the company's articles of association (公司章程), specifically related to changes in registered capital and share capital following a profit distribution plan. It includes details about the share capital increase and dividend distribution, and mentions that the amendments will be submitted to the shareholders' meeting for approval. The document is a formal announcement of these changes and the proposed amendments, not the actual amended articles or a full report. It is not a financial report, audit, or management report, but rather a regulatory announcement about corporate governance changes related to capital structure and company bylaws. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2026-04-15 Chinese
2025年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2025 年度内部控制评价报告' which translates to '2025 Annual Internal Control Evaluation Report'. It is a detailed report on the company's internal control evaluation for the fiscal year ending December 31, 2025. The content includes detailed descriptions of internal control scope, evaluation criteria, defect recognition standards, and conclusions on internal control effectiveness. It is not a brief announcement or a certification letter but a substantive report containing detailed internal control assessment and management information. This type of document aligns with an Audit Report / Information (AR) as it focuses on internal control evaluation and related audit matters rather than a full Annual Report (10-K) or other categories. The document length (9240 characters) and detailed content support this classification with high confidence. FY 2025
2026-04-15 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.